PhD Scientific Days 2025

Health Sciences III.

Clinical Outcomes and Safety of Endoscopic Transpapillary Pancreatic Duct Drainage for Pancreatic Pseudocysts: A Single-Center Tertiary Study

Előadó neve

Dr. Váncsa Szilárd, PhD

Neptun code

KXJRHR

Előadó munkahelye

Institute of Pancreatic Diseases and Centre for Translational Medicine, Semmelweis University

Előadó telefonszáma

+36-30/016-4408

Előadó e-mail címe

vancsaszilard@gmail.com

Az előadás címe

Clinical Outcomes and Safety of Endoscopic Transpapillary Pancreatic Duct Drainage for Pancreatic Pseudocysts: A Single-Center Tertiary Study

Szerző(k) neve és munkahelye

Szilárd Váncsa¹, Dorottya Tarján¹, Emese Fürst², Krisztina Tari², Balázs Lázár², Péter Sahin², Péter J Hegyi², Péter Hegyi¹, Bálint Erőss¹

1: Institute of Pancreatic Diseases and Centre for Translational Medicine, Semmelweis University, Budapest, Hungary
2: Institute of Pancreatic Diseases, Semmelweis University, Budapest, Hungary

Bemutatás módja

Szóbeli

Szekció

Health Sciences III.

Language of the presentation

English

Preferred session

Health Sciences

Összefoglaló szövege

AIMS
Pancreatic pseudocysts with ductal abnormalities present a therapeutic challenge after the resolution of acute pancreatitis. This study evaluated the clinical outcomes and safety of primary ERCP transpapillary pancreatic duct drainage.
METHODS
In this retrospective single-center study, all patients undergoing ERCP transpapillary drainage for pancreatic pseudocysts at Semmelweis University between July 28, 2023, and October 17, 2024, were included. Procedures were performed by experts with >10 years of experience, using rectal indomethacin and IV Ringer lactate for post-ERCP pancreatitis prophylaxis. Data on baseline characteristics, procedure details, outcomes, and adverse events (graded by AGREE) were collected. Follow-up included outpatient visits and phone consultations. Results were expressed as proportions with 95% CIs or means with SD.
RESULTS
Fourteen procedures were performed in 12 patients (64% female, mean age 62.8±14.5 years). Indications included pseudocyst progression (n=12, 86%) and icterus/cholangitis (n=4, 26%). Mean pseudocyst dimensions were 62.5±40.5 mm (AP), 43.2±27.4 mm (LL), and 65.9±28.0 mm (CC). Procedural success was 64.3% (CI: 35.7%–85.7%), with failures due to Vater papilla cannulation issues; these cases were either followed up, re-attempted with ERCP, or treated with EUS-guided gastrocystostomy. Stents (4–7 Fr, 5–11 cm) were chosen based on pancreatography or cannulation difficulty. In successful cases, amylase and lipase decreased by 396.6±80.7 and 441.0±159.3 units, respectively, by day 7. One AGREE Grade IIIa adverse event occurred, managed intra-procedurally without further intervention. Mean procedure time was 34.2±13.6 minutes. Follow-up showed pseudocyst regression in 5 cases (1 complete), 1 EUS-guided drainage, and 4 pending follow-up. One patient required ICU care for pancreatitis-related multi-organ failure; no deaths occurred.
CONCLUSIONS
ERCP transpapillary drainage achieves moderate success in treating pancreatic pseudocysts, leading to symptom and enzyme improvement in successful cases. EUS-guided options remain essential for ERCP failure.

University

Semmelweis University

Supervisor

Bálint Erőss

Publication of my abstract

I give consent to the publication of my abstract on the website of the congress.

phd.section.field

after finishing doctoral studies with absolutorium (PhD)

Kind

Szabad

Status

elfogadva

Accepted presentation method

szóbeli

Előadás fájl jóváhagyás

jóváhagyta

Előadó

9123

Start

10:00

End

10:15